secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059124
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics Q1 2024 net loss $28.1M; expands autoimmune plans
----------------------------------------------------------------------

- Net loss of $28.1M for Q1 2024 vs $31.3M in Q1 2023; R&D expenses $23.4M, down from $24.9M.
- Cash, cash equivalents and marketable securities $249.9M as of March 31, 2024; cash runway into 2026.
- Closed $60M private placement led by Bain Capital Life Sciences in April 2024.
- Plans additional regulatory filings for CNTY-101 in autoimmune diseases beyond SLE in H2 2024.
- FY2024 GAAP operating expense guidance raised to $150-160M (prior $135-145M) due to Clade acquisition and expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924059124/0001104659-24-059124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924059124/tm2413916d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer